Actively Recruiting
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2026-04-21
70
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC/GEJ adenocarcinoma after D2 or broader radical resection. After enrolling in the study, the subjects receive Sintilimab combined with oxaliplatin+Tegafur, Gimeracil and Oteracil Potassium Capsules (SOX) or oxaliplatin+Capecitabine (XELOX) , in which the combined chemotherapy is up to 8 cycles, and the total course of treatment was 16 cycles. The following-up of subjects includes adverse events、disease status、living conditions and the quality of life.
CONDITIONS
Official Title
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Histopathologically confirmed gastric or esophagogastric junction adenocarcinoma
- Pathological TNM stage IIIA to IIIC with PD-L1 CPS score of 1 or higher
- Patients have undergone D2 surgery
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Able to tolerate chemotherapy combined with immunotherapy
- Not pregnant and not planning to become pregnant within 6 months after treatment
- Willing to provide postoperative tumor tissue and peripheral blood samples
- Willing to sign informed consent form
You will not qualify if you...
- Received neoadjuvant treatments before surgery
- Evidence of tumor relapse or metastasis before starting adjuvant treatment
- Presence of other malignant tumors
- Unable to swallow tablets or capsules
- Any other condition deemed unsuitable for participation by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hodpital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China, 100021
Actively Recruiting
Research Team
L
LIN YANG, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here